Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Nivolumab induced hypopituitarism – case report (CROSBI ID 734143)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Lepetić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert Nivolumab induced hypopituitarism – case report // Libri oncologici : Croatian journal of oncology. 2022. str. 64-64

Podaci o odgovornosti

Lepetić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert

engleski

Nivolumab induced hypopituitarism – case report

Nowadays, immune checkpoint inhibitors (ICI) are a treatment of choice in a wide array of malignancies such as RCC, melanoma, or non - small cell lung carcinoma with significantly improved survival rates. Nivolumab targets programmed death 1 receptor (PD-1) - an effector ligand of immune checkpoint pathways, thus promoting an immunological reaction against cancer cells.Many immunerelated adverse effects are due to specific mechanisms of action.Although hypopituitarism is more frequent following combo therapy (ipilimumab with nivolumab), it rarely occurs in monotherapy with nivolumab. This care report aims to demonstrate occasional, but potentially severe entity that requires appropriate prompt diagnostic and therapeutic interventions. Patients should be closely monitored for a wide range of adverse events, keeping in mind that a wide range of immune-related adverse events can occur. Some of them are potentially severe, deferring treatment and compromising outcomes. At that point, prompt and focused care is needed to resolve the complications and to achieve maximum therapeutic potential.

immune checkpoint inhibitors (ICI), programmed death 1(PD-1) receptor, renal cell carcinoma (RCC), hypopituitarism

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

64-64.

2022.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Libri oncologici : Croatian journal of oncology

0300-8142

2584-3826

Podaci o skupu

Nepoznat skup

poster

29.02.1904-29.02.2096

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost